GENETIC TECHNOLOGIES LIMITED — Director's Dealing 2020

Jun 2, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Irwin Rubinstein
Date of last notice	30 December 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)	Irwin Biotech Nominees Pty Ltd
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	29 May 2020

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	f securities held prior to change		Irwin Biotech Nominees P/L <BIOA/C>6,200,000 ordinary shares	Irwin Biotech Nominees P/L <BIOA/C>6,200,000 ordinary shares
			Irwin Biotech Nominees Pty Ltd <BIOA/C>80,849,310 ordinary shares5,000,000 Performance Rights
			Irwin Biotech Nominees Pty Ltd
			2,000,000 ordinary sharesIrwin Biotech Nominees Pty Ltd
			26,582,700 ordinary shares (represented by44,305 American Depositary Receipts)
			RIP Opportunities Pty Ltd7,500,000 ordinary shares (represented by12,500 American Depositary Receipts)
			RIP OpportunitiFund A/C>	es Pty Ltd <PIR Super
			124,999,999 ordin125,000,000 Unlis	ary sharested Options
Class			Ordinary shares (rDepositary Recei	epresented by Americants)
Number acquired			60,000,000 Ordinary shares (represented by100,000 American Depositary Receipts)
Number disposed			Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation			US$210,000 (approximately AU$314,960)

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

	N f ii hld f h	N f ii hld f h	N f ii hld f h	N f ii hld f h
	o. o securtes e ater cange				Irwin BioteA/C>6,200,000 ordIrwin BiotecA/C>	h Nominees P/L <BIOinary sharesh Nominees Pty Ltd <BIO
					80,849,310 or	dinary shares
					5,000,000 Per	formance Rights
					Irwin Biotec	h Nominees Pty Ltd
					2,000,000 ordinary sharesIrwin Biotech Nominees Pty Ltd86,582,700 ordinary shares (represented by144,305 American Depositary Receipts)RIP Opportunities Pty Ltd7,500,000 ordinary shares (represented by12,500 American Depositary Receipts)
					RIP Opportunities PFund A/C>		ty Ltd <PIR Super
					124,999,999 ordinary125,000,000 Unlisted		sharesOptions
	Nature of changeExample: on-market trade off-market t	rade exercise of options issue			On market trade.
	, , ,of securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Detail of contract	Detail of contract	N/A	N/A
	Nature of interest		N/A
	Name of registered holder(if issued securities)		N/A
	Date of change		N/A
	No. and class of securities to which		N/A
	interest reNote: Details a	lated prior to changere onl reuired for a contract in
	relation to whic	y qh the interest has changed
	Itt	id	NA
	neres a	qure	/

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow thetrade to proceed during this period?
If prior written clearance was provided, on what date wasthis provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 4

01/01/2011